Inventaire - your friends and communities are your best library

Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors

Author

Robert Lambkin-Williams

Published in: Clinical Microbiology and Infection

Date of publication: January 1, 2003

Language: English

Main subject: pandemic, epidemic, disease outbreak, endemic disease

Bibliographic databases:

Cites articles 29

Date

Title

Authors

May 1, 1964

ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).
July 1, 1964

STRUCTURAL STUDIES ON THE PROTEIN SUBUNITS FROM THREE STRAINS OF INFLUENZA VIRUS.
April 1, 1970

In vivo selection of an influenza A2 strain resistant to amantadine,In vivo Selection of an Influenza A2 Strain resistant to Amantadine
August 1, 1970

Evaluation of amantadine in artificially induced A2 and B influenza
April 1, 1983

Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine
May 1, 1983

Structure of the catalytic and antigenic sites in influenza virus neuraminidase
November 1, 1985

The molecular basis of the specific anti-influenza action of amantadine
October 1, 1987

Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus
January 1, 1988

Clinical pharmacokinetics of amantadine hydrochloride.
February 1, 1989

Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A
October 1, 1993

Clinical effectiveness of influenza vaccination in Manitoba
June 3, 1993

Rational design of potent sialidase-based inhibitors of influenza virus replication
January 1, 1996

Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza
August 1, 1997

Design of aromatic inhibitors of influenza virus neuraminidase,Design of Aromatic Inhibitors of Influenza Virus Neuraminidase
September 1, 1997

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group
July 1, 1998

Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors,Structure−Activity Relationship Studies of Novel Carbocyclic Influenza Neuraminidase Inhibitors
January 1, 1999

Disarming flu viruses
July 19, 1999

Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping
August 1, 1999

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections
September 1, 1999

The economic impact of pandemic influenza in the United States: priorities for intervention.
February 16, 1999

Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene

, ,
November 1, 2000

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group
March 1, 2000

Influenza virus neuraminidase inhibitors
January 1, 2000

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study
May 1, 2000

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group
February 1, 2000

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group
March 1, 2000

Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology.
February 1, 2001

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial
August 1, 2002

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo

Article -

Welcome to inventaire

The library of your friends and communities

Learn more